Beta-Cyclodextrin Ophthalmic Compositions for Dry Eye and MGD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for meibomian gland dysfunction (MGD), blepharitis, and dry eye disease are ineffective in addressing the underlying causes and often lead to side effects due to the use of steroidal androgens, and there is a need for a safe and effective treatment that improves tear film stability.
Innovation Solution
A steroidal-androgen-free ophthalmic composition comprising beta-cyclodextrin derivatives, such as 2-hydroxypropyl-beta-cyclodextrin, is used to sequester cholesterol and inhibit immune activity, improving meibum composition and reducing inflammation, thereby treating MGD, blepharitis, and dry eye disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If steroidal androgens are used to treat MGD and dry eye disease, then meibomian gland function is improved, but side effects occur
Solution Approach 1:
The invention extracts and removes the harmful steroidal androgen component from the treatment while retaining the therapeutic benefits through alternative active ingredients (cyclodextrin derivatives) that sequester cholesterol and inhibit immune activity without causing hormonal side effects
Solution Approach 2:
The patent employs a non-steroidal, non-hormonal approach using cyclodextrin derivatives that act locally in the eye without systemic absorption, eliminating the need for long-term hormonal management and avoiding cumulative side effects
2Ease of operation
If current treatments are used for MGD, then some symptoms are relieved, but underlying causes are not addressed and tear film stability is not improved
Solution Approach 1:
The invention takes preliminary action by addressing the root cause of MGD through cholesterol sequestration and immune modulation before tear film instability occurs, preventing rather than merely treating symptoms
Solution Approach 2:
Cyclodextrin derivatives serve as intermediary molecules that sequester excess cholesterol in the meibomian glands, acting as a mediator to restore proper lipid balance and improve tear film stability without directly replacing hormones
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition significantly reduces symptoms like light sensitivity and blurred vision, with sustained effects lasting up to 5 months, while avoiding side effects associated with steroidal androgens.
Implementation Method 1
beta-cyclodextrin derivatives, such as 2-hydroxypropyl-beta-cyclodextrin, is used to sequester cholesterol
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
A method for treating an eye disease of an affected eye includes administering to the affected eye of a subject in need of such treatment a steroidal-androgen-free composition containing a therapeutically effective amount of beta-cyclodextrin derivative. The eye disease can be meibomian gland dysfunction, blepharitis, or dry eye disease. A steroidal-androgen-free composition includes a beta-cyclodextrin derivative as a sole active pharmaceutical ingredient. The steroidal-androgen-free composition is an ophthalmic composition.